Media Library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts

updated March 2021

Chief Executive Officer:
New York City
Web Address:
NYSE Listing:
Total Revenues:
$42.5 billion in 2020
R&D Investment:
$11.1 billion in 2020, which included the discovery and development of new medicines for patients
2020 Prioritized Brands Product Revenue:

REVLIMID® (lenalidomide), $12.1 billion

ELIQUIS® (apixaban), $9.1 billion

OPDIVO®(nivolumab), $7 billion

ORENCIA® (abatacept), $3.2 billion

POMALYST® (pomalidomide), $3.1 billion

SPRYCEL® (dasatinib), $2.1 billion

YERVOY® (ipilimumab), $1.7 billion

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.2 billion

EMPLICITI® (elotuzumab), $381 million

REBLOZYL® (luspatercept-aamt), $274 million

INREBIC® (fedratinib), $55 million

ONUREG® (azacitidine tablets), $17 million

ZEPOSIA® (ozanimod), $12 million

Please click on the product links to see the Full Prescribing Information for ABRAXANE®, ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG®OPDIVO®, ORENCIA®, POMALYST®, REBLOZYL®REVLIMID®SPRYCEL®, YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABRAXANE®, ELIQUIS®INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.

Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Scientific Media Resources
Disease State Infographics